CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

CluePoints Launches Risk-Based Monitoring Starter Pack to Drive Regulatory Compliance

The research undertaken by CluePoints highlighted the fact that many SMEs are unsure of how to embrace RBM and often how it might add significant value. The starter pack addresses this problem through the use of consultation on the ICH E6 addendum and RBM methodology. The aim is to help organizations fundamentally understand what the regulation wants, and demonstrate how a risk-based approach meets the compliance obligations and, at the same time, improves both cost and resource efficiencies.
The consultation also details the key software elements included in the starter pack. The software provides the necessary tools for organizations to start implementing a risk-based approach without overcomplicating the process, and gives users the freedom and opportunity to implement further RBM activities as and when required. Included in the starter pack are a Risk Assessment (RACT) Starter Kit, Key Risk Indicator Starter Kit, Patient Profiles Starter Kit, access to CluePoints proprietary Signals and Actions Tracking Management System and CluePoints Central Monitoring Platform Training.
“Since the introduction of the ICH E6 (R2) addendum, the industry has seen an increase in the implementation of a variety of RBM methodologies and technologies. However, we found through extensive research that SMEs are more reluctant to adopt as they perceive these types of approaches to be expensive and complicated. Consequently, they are generally unsure of the steps they need to take to implement an RBM strategy” comments Patrick Hughes, Chief Commercial Officer, CluePoints. “As we see the industry change and evolve, the starter pack is a fit-for-purpose, affordable way for SMEs to learn how the regulations will impact them, and to understand how an RBM approach can be implemented quickly and efficiently to suit their specific needs. This gives them a solution for ICH E6 compliance that will support them from pre-study risk assessment through to database lock and submission.”
For further information on the “CluePoints RBM and ICH E6 (R2) Starter Pack”, please visit http://cluepoints.com/risk-based-monitoring-starter-pack/

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026